Maegim한국어

셀리드

299660KOSDAQSector: Pharma & Biotech
₩1,033▼ 3.55%Market cap ₩30.5BAs of Jul 21, 2026 close · updated once daily
B
Grade B49.6 ptsTop 54% of 2,523 stocks
Financial strength
32.8
Growth momentum
74.9
Price attractiveness
50.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

32.8
How much debt does it carry relative to equity?
Debt-to-equity ratio
49.4%
✓ Above median · Top 47% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
83.0%
✗ Below median · Top 81.9% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-128.3%
✗ Below median · Top 77.2% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-16.3%
✗ Below median · Top 62.8% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

74.9
How much did revenue grow in a year?
Revenue growth (YoY)
112.3%
✓ Above median · Top 8% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
164.1%
✓ Above median · Top 3% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
5.3%
✓ Above median · Top 48.4% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
23.9%
✓ Above median · Top 41.1% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

50.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
✗ Below median · Top 91.3% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.41x
✓ Above median · Top 7.1% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15